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receptors, and although complement opsonization does
contribute to the recognition of particulate glucans, no
plasma molecules recognizing this carbohydrate struc-
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University of Oxford
South Parks Road ture have been identified. In contrast, the recognition of
-glucans appears to occur primarily in the hemolymphOxford, OX1 RE
United Kingdom of invertebrates via a number of completely unrelated
proteins, such as horseshoe crab factor G and gram-
negative binding proteins (GNBPs). Only one cellular
receptor has been shown to recognize -glucans in in--Glucans are structural cell wall polymers of many
fungi which possess immunomodulatory activities. Al- vertebrates, the Drosophila scavenger receptor (dSRCI).
Despite these differences, the recognition of -glucansthough the therapeutic benefits associated with these
compounds, particularly as anti-infective and antitu- in both systems results in the triggering of immune re-
sponses, designed primarily for the control of fungalmorigenic agents, have led to a large body of published
research over the last five decades, it is still unclear pathogens. The invertebrate recognition and response
to these carbohydrates is reviewed elsewhere (Muta andhow these carbohydrates mediate their effects. Recent
studies, however, are starting to shed some light on the Iwanaga, 1996).
cellular receptors and molecular mechanisms involved,
which also have direct relevance on the innate immune Historical Interest in -Glucans
response to fungal pathogens. The healing properties of mushrooms have been known
for thousands of years, with the first recorded report of
their medicinal qualities dating from around 3000 BC,
Over the last few years, there has been a resurgence of and although a number of fungal components have been
interest in innate immunity and the mechanisms utilized implicated in these properties, -glucans have attracted
by this evolutionarily ancient arm of the immune system to the most attention. The interest in these polymers origi-
distinguish self from nonself. What has become apparent nated in the early 1900s, when the ability of yeast to
from these studies is that the innate recognition of non- inactivate serum complement was first described. This
self is mediated largely through germline-encoded mol- led to the development of an insoluble yeast cell wall
ecules that recognize conserved microbial structures, particle, termed zymosan, which was subsequently used
the so-called “pattern recognition receptors” (Janeway, to help define the pathway of alternative complement acti-
1992). The recent discovery of the Toll-like receptors vation. Later studies showed that the direct intravenous
has also provided insights into how the inflammatory injection of zymosan could activate the immune system,
signals are generated in response to microbes. Despite stimulating protective host responses (see below). Al-
all these discoveries, however, little is known about the though these particles were found to consist of a variety
innate recognition of fungal pathogens or their compo- of components (including glucans, mannans, chitin, pro-
nents, even though fungal infections are becoming in- tein, and lipids), -glucan was identified as the biologi-
creasingly frequent in immunocompromised individuals cally active constituent (see Fitzpatrick and DiCarlo
worldwide and represent over 10% of all nosocomial [1964] for a more detailed review). Since the discovery
infections (van Burik and Magee, 2001). Here we will review of its stimulatory activities, zymosan has been a particle
the innate recognition and response to one group of con- of choice for many studies of immune function both in
served fungal components, the -glucans, and highlight vivo and in vitro, including inflammation, phagocytosis,
recent findings which have relevance both in terms of arachidonate release, and cell migration.
the immunomodulatory activities of these carbohydrates
and their importance in immunity to fungal pathogens. Biological Effects of -Glucans
-Glucans are a heterogeneous group of glucose poly- There is now a considerable body of published research
mers, consisting of a backbone of (1→3)-linked -D- detailing the biological effects of -glucans but, unfortu-
glucopyranosyl units with (1→6) linked side chains of nately, the literature is inconsistent and often contradic-
varying distribution and length. These polysaccharides tory. This has mainly been due to the use of -glucans
are major cell wall structural components in fungi and with different molecular weights (MW) and chemical
are also found in plants and some bacteria. As they are modifications, derived from a variety of fungal sources,
not found in animals, these carbohydrates are consid- including many common fungi and yeasts (Table 1). It is
ered to be classic pathogen-associated molecular pat- known that the immunomodulatory effects of -glucans
terns (Janeway, 1992) and are recognized by the innate are influenced by their degree of branching, polymer
immune system of vertebrates, as well as invertebrates. lengths, and tertiary structure, but there is still no con-
Surprisingly, the recognition of -glucans by verte- sensus on the basic structural requirements for biologi-
brates differs significantly from that of invertebrates. As cal activity. Although this review will focus primarily on
we shall see, vertebrate recognition of soluble-glucans fungal -glucans, -glucans from other sources appear
appears to occur exclusively via a number of cell surface to have similar properties.
In general, in vitro studies have suggested that large
MW or particulate -glucans (such as zymosan) can*Correspondence: gbrown@molbiol.ox.ac.uk
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al., 1991). In vivo, the clearance of-glucans depends onTable 1. Commonly Used Biologically Active -Glucans and Their
their MW, with low MW glucans being secreted throughFungal Sources
glomerular filtration and larger glucans being retained
-Glucan Source (common name)
primarily in the liver and degraded by Kupffer cells, a
zymosan Saccharomyces cerevisiae process which may take several weeks (Suda et al.,
glucan phosphate Saccharomyces cerevisiae 1996).
PGG-Glucan Saccharomyces cerevisiae Despite their beneficial uses, the stimulatory activities
lentinan Lentinus edodes (Shiitake mushroom)
of -glucans can also have detrimental effects on theschizophyllan Schizophyllum commune
host. Particulate -glucans, for example, induce granu-scleroglucan Sclerotium glucanicum
grifolan Grifola frondosa (Maitake mushrooms) loma formation after systemic administration, although
SSG-Glucan Sclerotinia sclerotiorum the development of soluble, biologically active, inter-
mediate MW -glucans has overcome this side effect
(Williams et al., 1996). In addition, these polymers can
induce lethal toxicity in mice, when combined with non-directly activate leukocytes, stimulating their phago-
steroidal anti-inflammatory drugs (Takahashi et al.,cytic, cytotoxic, and antimicrobial activities, including
2001), and may be involved in asthma, as a result ofthe production of reactive oxygen and nitrogen interme-
airway inflammation after inhalation (Rylander and Lin,diates. In addition, these carbohydrates stimulate the
2000).production of proinflammatory mediators, cytokines,
and chemokines, such as IL-8, IL-1, IL-6, and TNF-
(Czop, 1986; Williams et al., 1996). Stimulation by partic-
Leukocyte Receptors for -Glucansulate -glucans also enhances the ability of macro-
Evidence for cellular -glucan receptors first came fromphages to recognize and clear apoptotic cells, through
the demonstration that nonopsonic zymosan recogni-upregulation of the PS receptor (Fadok et al., 2000).
tion by human monocytes was -glucan dependentIntermediate or low MW -glucans (such as glucan
(Czop, 1986). It should be noted, however, that somephosphate) possess biological activity in vivo, but their
leukocyte populations also express other nonopsoniccellular effects are less clear. In some studies, these
receptors for zymosan, such as the mannose bindingglucans have been shown to activate leukocytes in vitro,
lectins (Taylor et al., 2002). -Glucan receptor activitypriming the cells for enhanced responses to a secondary
has subsequently been reported on a variety of otherchallenge, with, for example, LPS or intact bacteria. This
leukocytes, including macrophages, neutrophils, eosin-is thought to be mediated, at least in part, by the activa-
ophils, and NK cells, as well as on nonimmune cellstion of nuclear transcription factors, including NFB and
including endothelial cells, alveolar epithelial cells, andNF-IL-6 (Adams et al., 1997; Battle et al., 1998). Although
fibroblasts. Nonopsonic recognition of -glucans bythese glucans do not induce cytokines, such as TNF-
these cells has been ascribed to multiple receptors (Bat-and IL-1, there are some reports in which stimulation
tle et al., 1998), and indeed a number of -glucan recep-of IL-8 and IL-6 production occurred. In other studies,
tors have been identified, including CR3, lactosylcera-however, -glucans have been shown to suppress pro-
mide, scavenger receptors, and Dectin-1. Of theseinflammatory cytokine production in response to a sec-
receptors, however, only Dectin-1 has been clearlyondary challenge (Nakagawa et al., 2003). Understand-
shown to have a role in mediating the biological re-ing the molecular mechanisms behind the cellular
sponse to -glucans (see below).effects of these -glucans will help to solve these appar-
CR3ent contradictions. Very short -glucans (5000–10,000
CR3 is a heterodimeric integrin receptor, consisting ofMW; such as laminarin) are generally considered inactive
the m (CD11b) and 2 (CD18) chains and expressed on(see Bohn and BeMiller [1995] for a more detailed review
myeloid cells, NK cells, and selected lymphocytes. CR3on the structure-function relationships of -glucans).
functions as an adhesion molecule, through recognitionThe in vivo administration of -glucans has been
of endothelial ICAM-1, and as a phagocytic receptor forshown to potentiate host responses against a variety of
iC3b-opsonized particles, including opsonized particu-conditions, including tumor development and infection
late glucans. CR3 also possesses a lectin domain whichwith fungal, bacterial, viral, and protozoal pathogens
maps to a site C-terminal to the I-domain, and recognizes(Ross et al., 1999; Tzianabos, 2000). This has led to a
selected monosaccharides and a variety of -glucans,number of clinical trials using -glucans in tumor immu-
including zymosan, although the highest-affinity poly-notherapy and as prophylactic agents for the prevention
meric ligand contained very little-glucan and consistedof infections in surgical patients, with promising results.
mostly of mannose. The presence of this domain wasAlthough there has not yet been widespread pharma-
first noted using inhibitory monoclonal antibodies andceutical development of these compounds, they are be-
cells from patients with 2-integrin deficiencies (Ross eting used for tumor immunotherapy in Japan. The pub-
al., 1999). Although the CR3-dependent cytotoxicity oflished evidence of the beneficial effects of -glucans
iC3b-coated tumor cells is dependent on -glucan prim-has also led to a growing number of alternative medi-
ing of the leukocyte, the exact role of CR3 in the media-cines based on these polymers.
tion of the response to -glucans is unclear. PurifiedPerhaps another contributing factor to the biological
CR3 does not interact with these carbohydrates, andactivities of -glucans is their longevity in mammalian
leukocytes lacking CR3 can still bind and respond nor-systems. Vertebrate cells do not possess (1→3)-gluca-
mally to -glucans (Brown et al., 2002; Czop and Kay,nases and cannot rapidly degrade these carbohydrates,
metabolizing them slowly through oxidation (Nono et 1991; Muller et al., 1996; Van Strijp et al., 1993).
Minireview
313
Figure 1. Dectin-1 Mediates the Biological
Effects of -Glucans
Murine Dectin-1 possesses an ITAM motif in
the cytoplasmic tail which becomes phos-
phorylated after -glucan binding, generating
a signal at the cell surface which induces
phagocytosis and the respiratory burst. Zy-
mosan, which contains an unidentified TLR-2
ligand, stimulates both TLR-2 and Dectin-1,
inducing NFB activation and the production
of TNF- and IL-12. Also shown are the two
alternatively spliced functional human Dec-
tin-1 isoforms (GRA and GRB), which con-
tain ITAM motifs in their cytoplasmic tail and
presumably function in a similar manner.
Lactosylceramide functional (Willment et al., 2001). Dectin-1 recognizes
carbohydrates containing-1,3 and/or-1,6 glucan link-Lactosylceramide (LacCer; CDw17) is a glycosphingoli-
pid found in the plasma membranes of many cells and ages, and is expressed on cells of the monocyte/macro-
phage and neutrophil lineages, and at lower levels onwas identified as a -glucan receptor from biochemical
analyses of the interactions between PGG-glucan and dendritic cells and a subpopulation of splenic T cells
(Brown and Gordon, 2001; Taylor et al., 2002). Dectin-1isolated human leukocyte membrane components (Zim-
merman et al., 1998). It has been suggested that the was shown to be the major receptor for both soluble
and particulate-glucans on macrophages, and contrib-interaction of -glucan with this receptor can induce
macrophage inflammatory protein (MIP)-2 and the acti- uted to the recognition of opsonized glucan particles
(Brown et al., 2002). More importantly, Dectin-1 wasvation of NFB and can enhance the neutrophil oxidative
burst and antimicrobial functions, but the mechanisms recently demonstrated to mediate cellular responses to
particulate -glucans, including the production of proin-behind these activities are unknown.
Scavenger Receptors flammatory cytokines (Brown et al., 2003; see below).
Although no specific receptor has been identified, a
number of studies suggest that macrophage scavenger Molecular Mechanisms of -Glucan-Induced
Leukocyte Activationreceptors can recognize -glucans. The biochemical
demonstration that soluble -glucans could inhibit the The immunomodulatory activities of -glucans are still
far from being understood, particularly those of the inter-interactions of monocyte membranes with classic scav-
enger ligands is perhaps the best supporting evidence, mediate MW glucans, but recent studies have started
to shed some light on the mechanisms behind the proin-but may be attributed to the charge of the glucans tested
(Rice et al., 2002). flammatory response induced by large MW and particu-
late-glucans. In particular, following the demonstrationDectin-1
Originally identified as a receptor that recognized an that Toll-like receptors (TLR) have a central role in signal-
ing the induction of inflammatory reactions, TLR-2 wasunidentified ligand on T lymphocytes, promoting their
cellular proliferation (Ariizumi et al., 2000), Dectin-1 was shown to be critically required in the response to zymosan
(Underhill et al., 1999). TLR-2, which can interact with thisreidentified as a -glucan receptor from a macrophage
cDNA expression library screened with zymosan (Brown particle directly (Sato et al., 2003), forms functional pairs
with TLR-6 to induce cytokine and chemokine produc-and Gordon, 2001). The receptor possesses a single
nonclassical C-type carbohydrate recognition domain tion (Ozinsky et al., 2000). In addition, downstream com-
ponents of the TLR signaling pathway are required, in-(CRD) connected to the transmembrane region by a
stalk, and a cytoplasmic tail possessing an immunore- cluding MyD88 and NFB (Kataoka et al., 2002; Young
et al., 2001).ceptor tyrosine-based activation (ITAM) motif (Figure 1).
Human Dectin-1 differs from its murine counterpart in More recently, the proinflammatory response to zy-
mosan was shown to also require a signal from Dectin-1that it is alternatively spliced, in a cell-specific manner,
giving rise to several isoforms of which only two are (Figure 1). Using transfected macrophages and HEK293
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cells, it was demonstrated that for NFB activation and (Obayashi et al., 1995). Although the characteristics of
these carbohydrates and their effects during infectionthe production of TNF- and IL-12, signals from both
Dectin-1 and TLR-2 were needed (Brown et al., 2003; are unknown, it is possible that they may have modulat-
ing effects on the immune system. These circulatingGantner et al., 2003). Although the mechanism is un-
known, the generation of this response occurred at the -glucans have been proposed to be a diagnostic indi-
cator of mycotic infections, and at least one detectioncell surface and required a functional ITAM in cyto-
plasmic tail of Dectin-1. The ITAM motif became phos- kit is commercially available.
Finally, given the response of the immune system tophorylated after zymosan binding, suggesting that sig-
naling may occur in a fashion similar to that of other fungal -glucans, it is tempting to speculate that patho-
gens may avoid immune recognition by masking theirITAM-containing receptors, such as the Fc receptor.
In addition, Dectin-1 can trigger cellular responses to -glucan. Indeed, some pathogens, such as Cryptococ-
cus neoformans, avoid recognition through the produc--glucans independently of the TLRs, including phago-
cytosis and the oxidative burst (Brown and Gordon, tion of an extracellular capsule (Kozel, 1995). It is tempt-
ing to speculate that organisms also avoid immune2001; Gantner et al., 2003). These activities are also
mediated by signaling events triggered from the cyto- recognition by changing their cell wall composition dur-
ing infection, such as occurs with Paracoccidioides bra-plasmic tail. TLR-2, although recognizing some compo-
nent of zymosan (Gantner et al., 2003), does not recog- siliensis, which displays a transition from -glucan to
-glucan in the cell wall upon infection of the lungnize -glucans, and thus Dectin-1 signaling may play a
central role in immunomodulation mediated by these (Borges-Walmsley et al., 2002).
carbohydrates. In addition, this suggests that the strong
proinflammatory activities reported for some -glucans Conclusions
may be due to unidentified TLR2-triggering contami- In the defense against fungal pathogens, mammals have
nants. Characterization of the Dectin-1 knockout mouse, evolved mechanisms to recognize and respond to their
when available, should clarify these issues. In a broader conserved structural components, particularly -glucans.
context, these results represent a new paradigm in in- Our understanding of these mechanisms has not only
nate immunity, demonstrating for the first time that the provided insights into the workings of the innate immune
response to microbes, or their components, can require system but will allow the future exploitation of the thera-
signals from a specific receptor, in addition to those peutic potential of these carbohydrates.
mediated by the TLRs.
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